Search

Your search keyword '"Angevin, Eric"' showing total 320 results
Start Over Author "Angevin, Eric"
320 results on '"Angevin, Eric"'

1. The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape

Author

Lefebvre, Anne-Marie, Adam, Julien, Nicolazzi, Céline, Larois, Christelle, Attenot, Florence, Falda-Buscaiot, François, Dib, Colette, Masson, Nina, Ternès, Nils, Bauchet, Anne-Laure, Demers, Brigitte, Chadjaa, Mustapha, Sidhu, Sukhvinder, Combeau, Cécile, Soria, Jean-Charles, Scoazec, Jean-Yves, Naimi, Souad, Angevin, Eric, Chiron, Marielle, and Henry, Christophe

Published
2023
Full Text
View/download PDF

2. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

Author

Strickler, John H, Weekes, Colin D, Nemunaitis, John, Ramanathan, Ramesh K, Heist, Rebecca S, Morgensztern, Daniel, Angevin, Eric, Bauer, Todd M, Yue, Huibin, Motwani, Monica, Parikh, Apurvasena, Reilly, Edward B, Afar, Daniel, Naumovski, Louie, and Kelly, Karen

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prevention, Lung Cancer, Immunization, Lung, Clinical Research, Clinical Trials and Supportive Activities, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, Proto-Oncogene Proteins c-met, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThis first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody-drug conjugate of the anti-c-Met monoclonal antibody ABT-700 and monomethyl auristatin E.Materials and methodsFor dose escalation, three to six patients with advanced solid tumors were enrolled in eight cohorts (0.15 to 3.3 mg/kg). The dose-expansion phase enrolled patients with non-small-cell lung cancer (NSCLC) with c-Met-overexpressing tumors (c-Met positive; immunohistochemistry membrane H-score ≥ 150). Patients received Teliso-V monotherapy intravenously on day 1 once every 3 weeks. Safety, tolerability, pharmacokinetics, and maximum tolerated dose were determined.ResultsForty-eight patients were enrolled (median age, 65 years; 35.4% NSCLC; median four prior therapies). One patient each in the 3.0-mg/kg (n = 9) and 3.3-mg/kg (n = 3) cohorts experienced dose-limiting toxicities. Although the maximum tolerated dose was not formally identified, the recommended phase II dose was defined as 2.7 mg/kg on the basis of overall safety and tolerability. The most frequent treatment-emergent adverse events (any grade) were fatigue (42%), nausea (27%), constipation (27%), decreased appetite (23%), vomiting (21%), dyspnea (21%), diarrhea (19%), peripheral edema (19%), and neuropathy (17%). The most frequent Teliso-V-related grade ≥ 3 adverse events were fatigue, anemia, neutropenia, and hypoalbuminemia (4% each). Teliso-V and total antibody pharmacokinetics were approximately dose proportional, with a mean harmonic half-life of 2 to 4 days each. Prospective screening identified 35 (60%) of 58 patients with c-Met-positive NSCLC. Of 16 patients with c-Met-positive NSCLC who were treated with Teliso-V 2.4 to 3.0 mg/kg, three (18.8%; 95% CI, 4.1% to 45.7%) achieved a partial response (median response duration, 4.8 months; median progression-free survival, 5.7 months; 95% CI, 1.2 months to 15.4 months). No other patients experienced a response.ConclusionTeliso-V monotherapy demonstrated favorable safety and tolerability profiles, with encouraging evidence of antitumor activity in patients with c-Met-positive NSCLC.

Published
2018

3. Supplementary Methods S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Author

Peters, Solange, primary, Angevin, Eric, primary, Alonso-Gordoa, Teresa, primary, Rohrberg, Kristoffer, primary, Melero, Ignacio, primary, Mellado, Begoña, primary, Perez-Gracia, Jose-Luis, primary, Tabernero, Josep, primary, Adessi, Celine, primary, Boetsch, Christophe, primary, Watson, Carl, primary, Dal Porto, Joseph, primary, Dejardin, David, primary, Del Nagro, Christopher, primary, Nicolini, Valeria, primary, Evers, Stefan, primary, Klein, Christian, primary, Leutgeb, Barbara, primary, Pisa, Pavel, primary, Rossmann, Eva, primary, Saro, José, primary, Umana, Pablo, primary, Charo, Jehad, primary, Teichgräber, Volker, primary, and Steeghs, Neeltje, primary

Published
2024
Full Text
View/download PDF

4. Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Author

Peters, Solange, primary, Angevin, Eric, primary, Alonso-Gordoa, Teresa, primary, Rohrberg, Kristoffer, primary, Melero, Ignacio, primary, Mellado, Begoña, primary, Perez-Gracia, Jose-Luis, primary, Tabernero, Josep, primary, Adessi, Celine, primary, Boetsch, Christophe, primary, Watson, Carl, primary, Dal Porto, Joseph, primary, Dejardin, David, primary, Del Nagro, Christopher, primary, Nicolini, Valeria, primary, Evers, Stefan, primary, Klein, Christian, primary, Leutgeb, Barbara, primary, Pisa, Pavel, primary, Rossmann, Eva, primary, Saro, José, primary, Umana, Pablo, primary, Charo, Jehad, primary, Teichgräber, Volker, primary, and Steeghs, Neeltje, primary

Published
2024
Full Text
View/download PDF

5. Supplementary Table S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Author

Peters, Solange, primary, Angevin, Eric, primary, Alonso-Gordoa, Teresa, primary, Rohrberg, Kristoffer, primary, Melero, Ignacio, primary, Mellado, Begoña, primary, Perez-Gracia, Jose-Luis, primary, Tabernero, Josep, primary, Adessi, Celine, primary, Boetsch, Christophe, primary, Watson, Carl, primary, Dal Porto, Joseph, primary, Dejardin, David, primary, Del Nagro, Christopher, primary, Nicolini, Valeria, primary, Evers, Stefan, primary, Klein, Christian, primary, Leutgeb, Barbara, primary, Pisa, Pavel, primary, Rossmann, Eva, primary, Saro, José, primary, Umana, Pablo, primary, Charo, Jehad, primary, Teichgräber, Volker, primary, and Steeghs, Neeltje, primary

Published
2024
Full Text
View/download PDF

6. Data from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Author

Peters, Solange, primary, Angevin, Eric, primary, Alonso-Gordoa, Teresa, primary, Rohrberg, Kristoffer, primary, Melero, Ignacio, primary, Mellado, Begoña, primary, Perez-Gracia, Jose-Luis, primary, Tabernero, Josep, primary, Adessi, Celine, primary, Boetsch, Christophe, primary, Watson, Carl, primary, Dal Porto, Joseph, primary, Dejardin, David, primary, Del Nagro, Christopher, primary, Nicolini, Valeria, primary, Evers, Stefan, primary, Klein, Christian, primary, Leutgeb, Barbara, primary, Pisa, Pavel, primary, Rossmann, Eva, primary, Saro, José, primary, Umana, Pablo, primary, Charo, Jehad, primary, Teichgräber, Volker, primary, and Steeghs, Neeltje, primary

Published
2024
Full Text
View/download PDF

7. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Author

Peters, Solange, primary, Angevin, Eric, additional, Alonso-Gordoa, Teresa, additional, Rohrberg, Kristoffer, additional, Melero, Ignacio, additional, Mellado, Begoña, additional, Perez-Gracia, Jose-Luis, additional, Tabernero, Josep, additional, Adessi, Celine, additional, Boetsch, Christophe, additional, Watson, Carl, additional, Dal Porto, Joseph, additional, Dejardin, David, additional, Del Nagro, Christopher, additional, Nicolini, Valeria, additional, Evers, Stefan, additional, Klein, Christian, additional, Leutgeb, Barbara, additional, Pisa, Pavel, additional, Rossmann, Eva, additional, Saro, José, additional, Umana, Pablo, additional, Charo, Jehad, additional, Teichgräber, Volker, additional, and Steeghs, Neeltje, additional

Published
2024
Full Text
View/download PDF

8. Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Author

Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, You, Benoit, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Yamada, Taketo, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, and Morimoto, Chikao

Published
2021
Full Text
View/download PDF

10. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door

Author

Verlingue, Loic, Hollebecque, Antoine, Lacroix, Ludovic, Postel-Vinay, Sophie, Varga, Andrea, El Dakdouki, Yolla, Baldini, Capucine, Balheda, Rastilav, Gazzah, Anas, Michot, Jean-Marie, Marabelle, Aurélien, Mir, Olivier, Arnedos, Monica, Rouleau, Etienne, Solary, Eric, De Baere, Thierry, Angevin, Eric, Armand, Jean-Pierre, Michiels, Stefan, André, Fabrice, Deutsch, Eric, Scoazec, Jean-Yves, Soria, Jean-Charles, and Massard, Christophe

Published
2018
Full Text
View/download PDF

12. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

Author

Pruis, Melinda A, primary, Krebs, Matthew G, additional, Plummer, Ruth, additional, De Vos, Filip, additional, Angevin, Eric, additional, Prenen, Hans, additional, Forster, Martin D, additional, Clack, Glen, additional, Van der Aa, Annegret, additional, Tjwa, Marc, additional, Jansen, Ellen, additional, Perera, Timothy, additional, and Lolkema, Martijn P, additional

Published
2023
Full Text
View/download PDF

13. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Author

Bigot, Frédéric, Castanon, Eduardo, Baldini, Capucine, Hollebecque, Antoine, Carmona, Alberto, Postel-Vinay, Sophie, Angevin, Eric, Armand, Jean-Pierre, Ribrag, Vincent, Aspeslagh, Sandrine, Varga, Andrea, Bahleda, Rastislav, Menis, Jessica, Gazzah, Anas, Michot, Jean-Marie, Marabelle, Aurélien, Soria, Jean-Charles, and Massard, Christophe

Published
2017
Full Text
View/download PDF

14. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study

Author

Angevin, Eric, Cassier, Philippe A., Italiano, Antoine, Gonçalves, Anthony, Gazzah, Anas, Terret, Catherine, Toulmonde, Maud, Gravis, Gwenaëlle, Varga, Andrea, Parlavecchio, Cédric, Paci, Angelo, Poinsignon, Vianney, Soria, Jean-Charles, Drubay, Damien, and Hollebecque, Antoine

Published
2017
Full Text
View/download PDF

15. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

Author

Recondo, Gonzalo, Mahjoubi, Linda, Maillard, Aline, Loriot, Yohann, Bigot, Ludovic, Facchinetti, Francesco, Bahleda, Rastislav, Gazzah, Anas, Hollebecque, Antoine, Mezquita, Laura, Planchard, David, Naltet, Charles, Lavaud, Pernelle, Lacroix, Ludovic, Richon, Catherine, Lovergne, Aurelie Abou, De Baere, Thierry, Tselikas, Lambros, Deas, Olivier, Nicotra, Claudio, Ngo-Camus, Maud, Frias, Rosa L., Solary, Eric, Angevin, Eric, Eggermont, Alexander, Olaussen, Ken A., Vassal, Gilles, Michiels, Stefan, Andre, Fabrice, Scoazec, Jean-Yves, Massard, Christophe, Soria, Jean-Charles, Besse, Benjamin, and Friboulet, Luc

Published
2020
Full Text
View/download PDF

16. Supplementary Methods from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

17. Data from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure Legends from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 2 from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

21. Figure S3 from Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Author

Recondo, Gonzalo, primary, Mezquita, Laura, primary, Facchinetti, Francesco, primary, Planchard, David, primary, Gazzah, Anas, primary, Bigot, Ludovic, primary, Rizvi, Ahsan Z., primary, Frias, Rosa L., primary, Thiery, Jean Paul, primary, Scoazec, Jean-Yves, primary, Sourisseau, Tony, primary, Howarth, Karen, primary, Deas, Olivier, primary, Samofalova, Dariia, primary, Galissant, Justine, primary, Tesson, Pauline, primary, Braye, Floriane, primary, Naltet, Charles, primary, Lavaud, Pernelle, primary, Mahjoubi, Linda, primary, Abou Lovergne, Aurélie, primary, Vassal, Gilles, primary, Bahleda, Rastilav, primary, Hollebecque, Antoine, primary, Nicotra, Claudio, primary, Ngo-Camus, Maud, primary, Michiels, Stefan, primary, Lacroix, Ludovic, primary, Richon, Catherine, primary, Auger, Nathalie, primary, De Baere, Thierry, primary, Tselikas, Lambros, primary, Solary, Eric, primary, Angevin, Eric, primary, Eggermont, Alexander M., primary, Andre, Fabrice, primary, Massard, Christophe, primary, Olaussen, Ken A., primary, Soria, Jean-Charles, primary, Besse, Benjamin, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Data from Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Author

Gauci, Marie-Léa, primary, Lanoy, Emilie, primary, Champiat, Stéphane, primary, Caramella, Caroline, primary, Ammari, Samy, primary, Aspeslagh, Sandrine, primary, Varga, Andrea, primary, Baldini, Capucine, primary, Bahleda, Rastilav, primary, Gazzah, Anas, primary, Michot, Jean-Marie, primary, Postel-Vinay, Sophie, primary, Angevin, Eric, primary, Ribrag, Vincent, primary, Hollebecque, Antoine, primary, Soria, Jean-Charles, primary, Robert, Caroline, primary, Massard, Christophe, primary, and Marabelle, Aurélien, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 1 from Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

Author

Escudier, Bernard, primary, Grünwald, Viktor, primary, Ravaud, Alain, primary, Ou, Yen-Chuan, primary, Castellano, Daniel, primary, Lin, Chia-Chi, primary, Gschwend, Jürgen E., primary, Harzstark, Andrea, primary, Beall, Sarah, primary, Pirotta, Nicoletta, primary, Squires, Matthew, primary, Shi, Michael, primary, and Angevin, Eric, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Author

Angevin, Eric, primary, Tabernero, Josep, primary, Elez, Elena, primary, Cohen, Steven J., primary, Bahleda, Rastilav, primary, van Laethem, Jean-Luc, primary, Ottensmeier, Christian, primary, Lopez-Martin, Jose A., primary, Clive, Sally, primary, Joly, Florence, primary, Ray-Coquard, Isabelle, primary, Dirix, Luc, primary, Machiels, Jean-Pascal, primary, Steven, Neil, primary, Reddy, Manjula, primary, Hall, Brett, primary, Puchalski, Thomas A., primary, Bandekar, Rajesh, primary, van de Velde, Helgi, primary, Tromp, Brenda, primary, Vermeulen, Jessica, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Methods, Table 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Author

Angevin, Eric, primary, Tabernero, Josep, primary, Elez, Elena, primary, Cohen, Steven J., primary, Bahleda, Rastilav, primary, van Laethem, Jean-Luc, primary, Ottensmeier, Christian, primary, Lopez-Martin, Jose A., primary, Clive, Sally, primary, Joly, Florence, primary, Ray-Coquard, Isabelle, primary, Dirix, Luc, primary, Machiels, Jean-Pascal, primary, Steven, Neil, primary, Reddy, Manjula, primary, Hall, Brett, primary, Puchalski, Thomas A., primary, Bandekar, Rajesh, primary, van de Velde, Helgi, primary, Tromp, Brenda, primary, Vermeulen, Jessica, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 1 from Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

Author

Angevin, Eric, primary, Lopez-Martin, Jose A., primary, Lin, Chia-Chi, primary, Gschwend, Jürgen E., primary, Harzstark, Andrea, primary, Castellano, Daniel, primary, Soria, Jean-Charles, primary, Sen, Paramita, primary, Chang, Julie, primary, Shi, Michael, primary, Kay, Andrea, primary, and Escudier, Bernard, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 2 from Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

Author

Escudier, Bernard, primary, Grünwald, Viktor, primary, Ravaud, Alain, primary, Ou, Yen-Chuan, primary, Castellano, Daniel, primary, Lin, Chia-Chi, primary, Gschwend, Jürgen E., primary, Harzstark, Andrea, primary, Beall, Sarah, primary, Pirotta, Nicoletta, primary, Squires, Matthew, primary, Shi, Michael, primary, and Angevin, Eric, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 1 from Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

Author

Escudier, Bernard, primary, Grünwald, Viktor, primary, Ravaud, Alain, primary, Ou, Yen-Chuan, primary, Castellano, Daniel, primary, Lin, Chia-Chi, primary, Gschwend, Jürgen E., primary, Harzstark, Andrea, primary, Beall, Sarah, primary, Pirotta, Nicoletta, primary, Squires, Matthew, primary, Shi, Michael, primary, and Angevin, Eric, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure Legend from Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

Author

Escudier, Bernard, primary, Grünwald, Viktor, primary, Ravaud, Alain, primary, Ou, Yen-Chuan, primary, Castellano, Daniel, primary, Lin, Chia-Chi, primary, Gschwend, Jürgen E., primary, Harzstark, Andrea, primary, Beall, Sarah, primary, Pirotta, Nicoletta, primary, Squires, Matthew, primary, Shi, Michael, primary, and Angevin, Eric, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Data from Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Author

Recondo, Gonzalo, primary, Mezquita, Laura, primary, Facchinetti, Francesco, primary, Planchard, David, primary, Gazzah, Anas, primary, Bigot, Ludovic, primary, Rizvi, Ahsan Z., primary, Frias, Rosa L., primary, Thiery, Jean Paul, primary, Scoazec, Jean-Yves, primary, Sourisseau, Tony, primary, Howarth, Karen, primary, Deas, Olivier, primary, Samofalova, Dariia, primary, Galissant, Justine, primary, Tesson, Pauline, primary, Braye, Floriane, primary, Naltet, Charles, primary, Lavaud, Pernelle, primary, Mahjoubi, Linda, primary, Abou Lovergne, Aurélie, primary, Vassal, Gilles, primary, Bahleda, Rastilav, primary, Hollebecque, Antoine, primary, Nicotra, Claudio, primary, Ngo-Camus, Maud, primary, Michiels, Stefan, primary, Lacroix, Ludovic, primary, Richon, Catherine, primary, Auger, Nathalie, primary, De Baere, Thierry, primary, Tselikas, Lambros, primary, Solary, Eric, primary, Angevin, Eric, primary, Eggermont, Alexander M., primary, Andre, Fabrice, primary, Massard, Christophe, primary, Olaussen, Ken A., primary, Soria, Jean-Charles, primary, Besse, Benjamin, primary, and Friboulet, Luc, primary

Published
2023
Full Text
View/download PDF

31. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

Author

Pruis, Melinda A., Krebs, Matthew G., Plummer, Ruth, De Vos, Filip, Angevin, Eric, Prenen, Hans, Forster, Martin D., Clack, Glen, Van Der Aa, Annegret, Tjwa, Marc, Jansen, Ellen, Perera, Timothy, Lolkema, Martijn P., Pruis, Melinda A., Krebs, Matthew G., Plummer, Ruth, De Vos, Filip, Angevin, Eric, Prenen, Hans, Forster, Martin D., Clack, Glen, Van Der Aa, Annegret, Tjwa, Marc, Jansen, Ellen, Perera, Timothy, and Lolkema, Martijn P.

Abstract

Introduction: Targeted therapy in non-small cell lung cancer (NSCLC) patients with mesenchymal epithelial transition (MET) exon 14 skipping mutations (METex14) and MET amplifications has improved patients' outcomes. The development of more potent MET kinase inhibitors could further benefit these patients. The aim of this trial is to determine the safety and recommended phase 2 dose (RP2D) of OMO-1 (an oral dual MET kinase/OCT-2 inhibitor) and to assess preliminary clinical efficacy in METex14-positive NSCLC and other MET-positive solid tumors. Materials and Methods: This was a first-in-patient, open-label, multicenter study of OMO-1 in patients with locally advanced or metastatic solid malignancies. A standard 3 + 3 dose escalation design was utilized starting at a dose level of 100 mg BID continuously. Preliminary efficacy was investigated in patients with METex14-positive NSCLC, and MET amplified NSCLC and other solid tumors (MET basket). Results: In the dose-escalation part, 24 patients were included in 5 dose levels ranging from 100 mg twice daily (BID) to 400 mg BID. Most common adverse events (≥ 20%) were nausea, fatigue, vomiting, increased blood creatinine, and headache. The RP2D was determined at 250 mg BID. In the expansion cohorts, 15 patients were included (10 in METex14-positive NSCLC cohort and 5 in MET basket cohort) and received either 200 or 250 mg BID. Eight out of the 10 patients with METex14 positive NSCLC had stable disease as the best response. Conclusion: OMO-1 was tolerated at the dose of 250 mg BID and shows initial signs of MET inhibition and anti-tumor activity in METex14 mutated NSCLC patients.

Published
2023

32. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

Author

MS Medische Oncologie, Cancer, Pruis, Melinda A, Krebs, Matthew G, Plummer, Ruth, De Vos, Filip, Angevin, Eric, Prenen, Hans, Forster, Martin D, Clack, Glen, Van der Aa, Annegret, Tjwa, Marc, Jansen, Ellen, Perera, Timothy, Lolkema, Martijn P, MS Medische Oncologie, Cancer, Pruis, Melinda A, Krebs, Matthew G, Plummer, Ruth, De Vos, Filip, Angevin, Eric, Prenen, Hans, Forster, Martin D, Clack, Glen, Van der Aa, Annegret, Tjwa, Marc, Jansen, Ellen, Perera, Timothy, and Lolkema, Martijn P

Published
2023

34. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

Author

Camidge, D. Ross, primary, Barlesi, Fabrice, additional, Goldman, Jonathan W., additional, Morgensztern, Daniel, additional, Heist, Rebecca, additional, Vokes, Everett, additional, Spira, Alex, additional, Angevin, Eric, additional, Su, Wu-Chou, additional, Hong, David S., additional, Strickler, John H., additional, Motwani, Monica, additional, Dunbar, Martin, additional, Parikh, Apurvasena, additional, Noon, Elysa, additional, Blot, Vincent, additional, Wu, Jun, additional, and Kelly, Karen, additional

Published
2023
Full Text
View/download PDF

35. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

Author

Hamid, Omid, primary, Chiappori, Alberto A, additional, Thompson, John A, additional, Doi, Toshihiko, additional, Hu-Lieskovan, Siwen, additional, Eskens, Ferry A L M, additional, Ros, Willeke, additional, Diab, Adi, additional, Spano, Jean-Philippe, additional, Rizvi, Naiyer A, additional, Wasser, Jeffrey S, additional, Angevin, Eric, additional, Ott, Patrick A, additional, Forgie, Alison, additional, Yang, Wenjing, additional, Guo, Cen, additional, Chou, Jeffrey, additional, and El-Khoueiry, Anthony B, additional

Published
2022
Full Text
View/download PDF

36. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

Author

Hamid, Omid, Chiappori, Alberto A., Thompson, John A., Doi, Toshihiko, Hu-Lieskovan, Siwen, Eskens, Ferry A.L.M., Ros, Willeke, Diab, Adi, Spano, Jean Philippe, Rizvi, Naiyer A., Wasser, Jeffrey S., Angevin, Eric, Ott, Patrick A., Forgie, Alison, Yang, Wenjing, Guo, Cen, Chou, Jeffrey, El-Khoueiry, Anthony B., Hamid, Omid, Chiappori, Alberto A., Thompson, John A., Doi, Toshihiko, Hu-Lieskovan, Siwen, Eskens, Ferry A.L.M., Ros, Willeke, Diab, Adi, Spano, Jean Philippe, Rizvi, Naiyer A., Wasser, Jeffrey S., Angevin, Eric, Ott, Patrick A., Forgie, Alison, Yang, Wenjing, Guo, Cen, Chou, Jeffrey, and El-Khoueiry, Anthony B.

Abstract

BACKGROUND: Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This first-in-human, multicenter, open-label, phase I, dose-escalation/dose-expansion study explored safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of ivuxolimab+utomilumab in patients with advanced solid tumors. METHODS: Dose-escalation: patients with advanced bladder, gastric, or cervical cancer, melanoma, head and neck squamous cell carcinoma, or non-small cell lung cancer (NSCLC) who were unresponsive to available therapies, had no standard therapy available or declined standard therapy were enrolled into five dose cohorts: ivuxolimab (0.1-3 mg/kg every 2 weeks (Q2W)) intravenously plus utomilumab (20 or 100 mg every 4 weeks (Q4W)) intravenously. Dose-expansion: patients with melanoma (n=10) and NSCLC (n=20) who progressed on prior anti-programmed death receptor 1/programmed death ligand-1 and/or anti-cytotoxic T-lymphocyte-associated antigen 4 (melanoma) received ivuxolimab 30 mg Q2W intravenously plus utomilumab 20 mg Q4W intravenously. Adverse events (AEs) were graded per National Cancer Institute Common Terminology Criteria for Adverse Events V.4.03 and efficacy was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and immune-related RECIST (irRECIST). Paired tumor biopsies and whole blood were collected to assess pharmacodynamic effects and immunophenotyping. Whole blood samples were collected longitudinally for immunophenotyping. RESULTS: Dose-escalation: 57 patients were enrolled; 2 (3.5%) patients with melanoma (0.3 mg/kg+20 mg and 0.3 mg/kg+100 mg) achieved partial response (PR), 18 (31.6%) patients achieved stable disease (SD); the disease control rate (DCR) was 35.1% across all dose levels. Dose-expansion: 30 patients were enrolled; 1 patient with NSCLC achieved PR lasting >77 weeks. Seven of 10 patients with melanoma (70%) and 7 of 20

Published
2022

37. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

Author

Camidge, D. Ross, primary, Barlesi, Fabrice, additional, Goldman, Jonathan W., additional, Morgensztern, Daniel, additional, Heist, Rebecca, additional, Vokes, Everett, additional, Angevin, Eric, additional, Hong, David S., additional, Rybkin, Igor I., additional, Barve, Minal, additional, Bauer, Todd M., additional, Delmonte, Angelo, additional, Dunbar, Martin, additional, Motwani, Monica, additional, Parikh, Apurvasena, additional, Noon, Elysa, additional, Wu, Jun, additional, Blot, Vincent, additional, and Kelly, Karen, additional

Published
2022
Full Text
View/download PDF

39. 284 Integrated molecular characterization of primary resistance mechanisms to immune checkpoint blockade in advanced non-small cell lung carcinoma (a-NSCLC)

Author

Besse, Benjamin, primary, Colette, DIB, additional, Marquez, Eladio, additional, Lee, Joon Sang, additional, Yan, Shu, additional, Chiron, Marielle, additional, Combeau, Cecile, additional, Biancotto, Angelique, additional, Blanc-Durand, Félix, additional, Aldea, Mihaela, additional, Planchard, David, additional, Scoazec, Jean-Yves, additional, Lacroix, Ludovic, additional, Rouleau, Etienne, additional, Chaput-Gras, Nathalie, additional, Rafie, Saloomeh, additional, Marabelle, Aurélien, additional, Angevin, Eric, additional, and Pollard, Jack, additional

Published
2021
Full Text
View/download PDF

40. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

Author

Camidge, D. Ross, primary, Morgensztern, Daniel, additional, Heist, Rebecca S., additional, Barve, Minal, additional, Vokes, Everett, additional, Goldman, Jonathan W., additional, Hong, David S., additional, Bauer, Todd M., additional, Strickler, John H., additional, Angevin, Eric, additional, Motwani, Monica, additional, Parikh, Apurvasena, additional, Sun, Zhaowen, additional, Bach, Bruce Allen, additional, Wu, Jun, additional, Komarnitsky, Philip B., additional, and Kelly, Karen, additional

Published
2021
Full Text
View/download PDF

41. Additional file 7 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Author

Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, Benoit You, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Taketo Yamada, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, and Morimoto, Chikao

Abstract

Additional file 7: Table S6. Correlation between serum sCD26/DPP4 titer variation (%) and tumor volume change (%) or PFS (days) in 12 MM cases with Q2W administration by PPMC or SRDC analysis.

Published
2021
Full Text
View/download PDF

42. Additional file 2 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Author

Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, Benoit You, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Taketo Yamada, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, and Morimoto, Chikao

Abstract

Additional file 2: Table S2. Detailed information about 26 evaluable cases

Published
2021
Full Text
View/download PDF

43. Additional file 6 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Author

Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, Benoit You, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Taketo Yamada, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, and Morimoto, Chikao

Subjects
sense organs
Abstract

Additional file 6: Table S5. Correlation between serum sCD26/DPP4 titer variation (%) and tumor volume change (%) or PFS (days) in 19 MM cases by PPMC or SRDC analysis.

Published
2021
Full Text
View/download PDF

44. Additional file 8 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Author

Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, Benoit You, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Taketo Yamada, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, and Morimoto, Chikao

Abstract

Additional file 8: Table S7. Correlation between serum sCD26/DPP4 titer variation (%) and tumor volume change (%) or PFS (days) in 9 MM, male cases with Q2W administration by PPMC or SRDC analysis.

Published
2021
Full Text
View/download PDF

45. Additional file 3 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Author

Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, Benoit You, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Taketo Yamada, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, and Morimoto, Chikao

Abstract

Additional file 3: Figure S1. Correlation between serum soluble CD26 level and DPP4 enzyme activity

Published
2021
Full Text
View/download PDF

46. Additional file 9 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Author

Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, Benoit You, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Taketo Yamada, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, and Morimoto, Chikao

Abstract

Additional file 9: Figure S2. Cell surface protein expression of CD26 on the human tumor and non-tumor cells.

Published
2021
Full Text
View/download PDF

47. Additional file 1 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Author

Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, Benoit You, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Taketo Yamada, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, and Morimoto, Chikao

Subjects
sense organs, skin and connective tissue diseases
Abstract

Additional file 1: Table S1. Demographic chart of 26 evaluable cases on administration frequency and dosage, gender, PFS, age, BMI, RECIST evaluation, tumor volume change and serum sCD26/DPP4 titer change

Published
2021
Full Text
View/download PDF

48. Additional file 5 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Author

Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, Benoit You, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Taketo Yamada, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, and Morimoto, Chikao

Abstract

Additional file 5: Table S4. Correlation between serum sCD26/DPP4 titer variation (%) and tumor volume change (%) or PFS (days) in 14 male cases with Q2W administration by PPMC or SRDC analysis

Published
2021
Full Text
View/download PDF

49. Additional file 4 of Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Author

Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, Benoit You, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Taketo Yamada, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, and Morimoto, Chikao

Abstract

Additional file 4: Table S3. Correlation between serum sCD26/DPP4 titer variation (%) and tumor volume change (%) or PFS (days) in 18 cases with Q2W administration by PPMC or SRDC analysis

Published
2021
Full Text
View/download PDF

50. Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).

Author

Balar, Arjun Vasant, primary, Moreno, Victor, additional, Angevin, Eric, additional, Gan, Hui Kong, additional, Vieito, Maria, additional, Italiano, Antoine, additional, Danielli, Riccardo, additional, Massarelli, Erminia, additional, Opdam, Frans, additional, Chisamore, Michael Jon, additional, Rogan, Debra, additional, Ji, Xiao, additional, Henry, Courtney, additional, Ellis, Catherine Elizabeth, additional, Ballas, Marc S., additional, Hoos, Axel, additional, and Ricci, Francesco, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results